Fundraising FoxSahsen Ventures — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Enzyme develops a Quality Management System (QMS) software platform for life science companies including drug, biologic, device, and digital product manufacturers, designed to streamline regulatory workflows and generate FDA-ready documentation.
Enterprise SoftwareHealthtechMedical DevicesSaaSSan Francisco, US
Jared Seehafer(CEO)inJacob Graham(Vice President QA/RA)inAl Abut(Director of Design)Ryan Stellar(Vice President Product)Alex Speller(Head of Engineering)Mark Krempley(Vice President Operations)
Co-investorsDCVC (Data Collective)Soma CapitalY CombinatorAg Startup Engine SeedHack VCInformed Ventures Advisors, Llc+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.